Projet d’expansion en grade clinique de cellules myéloïdes suppressives "e-MDSC"

Le résumé fourni par la source

Allogeneic transplantation, whether involving hematopoietic stem cells (allo-HSC) or solid organs, currently represents the only curative treatment for certain severe diseases. However, it is often accompanied by a potentially lethal allo-immune response, linked to the uncontrolled activation of T lymphocytes. Conventional immunosuppressive treatments are often non-specific, toxic in the long term, and cause undesirable side effects. A promising alternative lies in cell therapies with immunoregulatory purposes. Myeloid-Derived Suppressor Cells (MDSCs) are very good candidates because they are capable of specifically controlling the activation and proliferation of T lymphocytes. In our laboratory, we have developed a clinically compatible method to generate large numbers of MDSCs from immature blood CD34⁺ cells derived from a healthy voluntary donor mobilized by a growth factor, or from placental cord blood. This project, supported by SATT Sayens, led to the filing of patent no. EP23307324 on 12/21/24. The main objectives of this work were, on the one hand, to improve the quantity of MDSCs produced with a view to potential application in humans and, on the other hand, to better characterize the phenotypic identity of the cell component through relevant cell surface markers, confirmed by single-cell RNA sequencing, and to dissect the mechanisms deployed by these cells to regulate T lymphocyte proliferation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.